Martha Gulati and C. Michael Gibson highlight FDA approval of Eli Lilly’s once-daily oral GLP-1 orforglipron, positioning it as a convenient new obesity treatment option with meaningful average weight loss.
FDA approved #Orforglipron (#Foundayo), Eli Lilly’s new once-daily oral GLP-1 pill for obesity.
✅average weight loss: 11% of their body weight
FDA approves Lilly's oral GLP-1 #Foundayo (#orforglipron), the fastest approval of an new molecular entity since 2002.
FDA approved #Orforglipron (#Foundayo)
once-daily oral GLP-1 pill for obesity
average weight loss: 11% of their body weight
A game-changer for weight loss!
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new expert voices, debates, and emerging ideas.
← Back to Healthcare